Luye Pharma Group Ltd (2186):企業の財務・戦略的SWOT分析

◆英語タイトル:Luye Pharma Group Ltd (2186) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C14894
◆発行会社(調査会社):GlobalData
◆発行日:2019年3月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:中国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD300 ⇒換算¥33,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD600 ⇒換算¥66,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD900 ⇒換算¥99,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Luye Pharma Group Ltd (Luye Pharma Group) is a drug company that manufactures, develops, discovers, and commercializes novel formulations, natural drugs, medicinal products, pharmaceutical products, and biotechnology products. The group’s products include paclitaxel liposome, lentinan, sodium glycididazole, arsenious acid, and xuezhikang, among others. It also provides amifostine, oxaliplatin, meloxicam, pioglitazone hydrochloride, reduced glutathione, and selegiline hydrochloride, among others. Luye Pharma Group’s products are used in therapeutic areas including endocrinology, oncology, cardiovascular, orthopedics, gastroenterology, hepatology, gynecology, and central nervous system, among others. The group offers its products through its distributors located across China. Luye Pharma Group is headquartered in Yantai, China.

Luye Pharma Group Ltd Key Recent Developments

Jan 17,2019: AstraZeneca licences Luye Pharma cholesterol drug in China
Sep 20,2018: Luye Pharma Strengthens Its Global CNS Portfolio with Patch Product for the Treatment of Alzheimer’s Soon to be Launched in China
Aug 26,2018: Luye Pharma Group reports interim results for the six months ended 30 June 2018
Aug 03,2018: Luye Pharma: Change of information of director

This comprehensive SWOT profile of Luye Pharma Group Ltd provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Luye Pharma Group Ltd including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

【レポートの目次】

Table of Contents

Section 1 – About the Company

Luye Pharma Group Ltd – Key Information
Luye Pharma Group Ltd – Overview
Luye Pharma Group Ltd – Key Employees
Luye Pharma Group Ltd – Key Employee Biographies
Luye Pharma Group Ltd – Key Operational Heads
Luye Pharma Group Ltd – Major Products and Services
Luye Pharma Group Ltd – History
Luye Pharma Group Ltd – Company Statement
Luye Pharma Group Ltd – Locations And Subsidiaries
Luye Pharma Group Ltd – Key Manufacturing facilities
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis

Luye Pharma Group Ltd – Business Description
Luye Pharma Group Ltd – Corporate Strategy
Luye Pharma Group Ltd – SWOT Analysis
SWOT Analysis – Overview
Luye Pharma Group Ltd – Strengths
Luye Pharma Group Ltd – Weaknesses
Luye Pharma Group Ltd – Opportunities
Luye Pharma Group Ltd – Threats
Luye Pharma Group Ltd – Key Competitors

Section 3 – Company Financial Performance Charts

Luye Pharma Group Ltd – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts

Section 4 – Appendix

Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

Note*: Some sections may be missing if data is unavailable for the company

List of Tables

Luye Pharma Group Ltd, Key Information
Luye Pharma Group Ltd, Key Ratios
Luye Pharma Group Ltd, Share Data
Luye Pharma Group Ltd, Major Products and Services
Luye Pharma Group Ltd, History
Luye Pharma Group Ltd, Key Employees
Luye Pharma Group Ltd, Key Employee Biographies
Luye Pharma Group Ltd, Key Operational Heads
Luye Pharma Group Ltd, Other Locations
Luye Pharma Group Ltd, Subsidiaries
Luye Pharma Group Ltd, Key Manufacturing facilities
Luye Pharma Group Ltd, Key Competitors
Luye Pharma Group Ltd, SWOT Analysis
Luye Pharma Group Ltd, Ratios based on current share price
Luye Pharma Group Ltd, Annual Ratios
Luye Pharma Group Ltd, Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures

Luye Pharma Group Ltd, Performance Chart
Luye Pharma Group Ltd, Ratio Charts

★海外企業調査レポート[Luye Pharma Group Ltd (2186):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • La Jolla Institute for Allergy & Immunology:製薬・医療:M&Aディール及び事業提携情報
    Summary La Jolla Institute for Allergy & Immunology (LIAI) is a biomedical research institute that offers solutions for infectious agents and cancers. The institute provides research on prevention, treatment, and cure of immune system diseases. Its activities include disease research on allergy and …
  • Tenaga Nasional Bhd (TENAGA):企業の財務・戦略的SWOT分析
    Tenaga Nasional Bhd (TENAGA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Concord Medical Services Holdings Ltd (CCM):製薬・医療:M&Aディール及び事業提携情報
    Summary Concord Medical Services Holdings Ltd (CMS) is a diagnostic imaging center that offers clinical support services and laboratory services. The center offers radiotherapy and diagnostic imaging equipment services such as head gamma knife systems, body gamma knife systems and linear accelerator …
  • ThromboGenics NV (THR)-製薬・医療分野:企業M&A・提携分析
    Summary ThromboGenics NV (ThromboGenics) is a biotechnology company, which develops and commercializes ophthalmic and cancer medicines. The company’s ocriplasmin, a recombinant derivative of the plasmin protein, is commercialized as Jetrea in the US to treat symptomatic vitreomacular adhesion (VMA) …
  • Saudi Arabian Oil Co:企業の戦略的SWOT分析
    Saudi Arabian Oil Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Novo Nordisk AS (NOVO B)-製薬・医療分野:企業M&A・提携分析
    Summary Novo Nordisk A/S (Novo Nordisk), a subsidiary of Novo A/S discovers, develops and manufactures innovative biological medicines. It focuses at developing drugs for treating diabetes and other serious chronic conditions including hemophilia, growth disorders and obesity. The company’s product …
  • Famy Care Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Famy Care Ltd (Famy Care) is a healthcare products provider that research, develops and manufactures female reproductive health care products. The company manufactures hormonal and reproductive health care products including famy care. Its hormonal formulation products include combined oral …
  • Kyokuyo Co., Ltd.
    Kyokuyo Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Kyokuyo Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • TauRx Pharmaceuticals Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary TauRx Pharmaceuticals Ltd (TauRx) discovers, develops and commercializes treatments and diagnostics for Alzheimer's disease and other neurodegenerative diseases. Its pipeline products include LMTX, a tau aggregation inhibitor (TAI) for Alzheimer’s and Behavioural variant frontotemporal demen …
  • Mgm China Holdings Ltd
    Mgm China Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary Mgm China Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Hibu Group Limited:戦略・SWOT・企業財務分析
    Hibu Group Limited - Strategy, SWOT and Corporate Finance Report Summary Hibu Group Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Montana Exploration Corp. (MTZ)-石油・ガス分野:企業M&A・提携分析
    Summary Montana Exploration Corp. (Montana Exploration) is an upstream energy company that acquires, exploits, explores and produces from oil and gas fields in Alberta and Montana. It has significant interests and assets in Blaine County, Montana and Viking Kinsella, Alberta. The company focuses on …
  • Sagent Pharmaceuticals Inc:医療機器:M&Aディール及び事業提携情報
    Summary Sagent Pharmaceuticals Inc (Sagent), formerly Sagent Holding Co, a subsidiary of Nichi-Iko Pharmaceutical Co Ltd, is a biopharmaceutical company that develops and manufactures injectable products. The company offers products such as amikacin sulfate injection, USP, ampicillin and sulbactam f …
  • Aptiv Plc:企業の戦略・SWOT・財務分析
    Aptiv Plc - Strategy, SWOT and Corporate Finance Report Summary Aptiv Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Grasim Industries Ltd (GRASIM):企業の財務・戦略的SWOT分析
    Grasim Industries Ltd (GRASIM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Helomics Corp-製薬・医療分野:企業M&A・提携分析
    Summary Helomics Corp(Helomics) is a life science company that develops and offers precision medicine support tools and services for cancer treatment. The company’s products include chemofx, biospecifx, genefx colon and genefx lung. Its chemofx is a drug response marker, which is used to test tumor …
  • Witte Molen NV:企業の戦略・SWOT・財務分析
    Witte Molen NV - Strategy, SWOT and Corporate Finance Report Summary Witte Molen NV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • ServiceNow Inc (NOW):企業の財務・戦略的SWOT分析
    ServiceNow Inc (NOW) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Asian Infrastructure Investment Bank:電力:M&Aディール及び事業提携情報
    Summary Asian Infrastructure Investment Bank (AIIB) is a multilateral financial institution. The company develops infrastructure and other productive sectors. It provides sovereign and non-sovereign finance for sustainable projects in energy and power, transportation and telecommunications, rural in …
  • Jordan Ahli Bank PSC:企業の戦略・SWOT・財務分析
    Jordan Ahli Bank PSC - Strategy, SWOT and Corporate Finance Report Summary Jordan Ahli Bank PSC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆